Lunai Bioworks Inc., an AI-powered drug discovery and biodefense company, has unveiled its new transformer-based platform designed to improve safety in generative AI applications for drug discovery. The platform integrates a proprietary neurotoxicity intelligence layer into large language model pipelines to expedite therapeutic discovery while preventing the misuse of AI in creating hazardous compounds. This technology utilizes extensive neurotoxicity datasets and virtual chemical screening to identify potentially toxic novel compounds, thus addressing dual-use concerns in AI-driven healthcare innovation. The platform's launch positions Lunai Bioworks at the forefront of merging biodefense with pharmaceutical innovation, responding to global calls for robust safeguards against AI-enabled biothreats. The research results have been announced, but it is not specified if they have been or will be presented at a specific scientific conference or publication.